Marina Chiara Garassino
Overview
Explore the profile of Marina Chiara Garassino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
161
Citations
4946
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garassino M, He Y, Ahn M, Orlov S, Potter V, Kato T, et al.
Lung Cancer
. 2025 Mar;
202:108417.
PMID: 40056874
Introduction: This post-hoc analysis of the registrational FLAURA study and AURA program reports long-term safety data in epidermal growth factor receptor-mutated (EGFRm), advanced non-small cell lung cancer (NSCLC) treated with...
2.
Urtecho S, Provenzano L, Spagnoletti A, Bottiglieri A, Pircher C, Massa G, et al.
Lung Cancer
. 2024 Dec;
199:108051.
PMID: 39740426
Introduction: KRAS mutation the most common molecular alteration in advanced non-small cell lung cancer (NSCLC) and is associated with an unfavourable prognosis, largely due to the lack of targeted therapeutic...
3.
Peng Y, Karpus J, Patel J, Vokes E, Garassino M, Lugtu K, et al.
Cancer Commun (Lond)
. 2024 Nov;
45(1):51-55.
PMID: 39527101
No abstract available.
4.
Ricciuti B, Garassino M
J Thorac Oncol
. 2024 Jun;
19(6):877-882.
PMID: 38849167
No abstract available.
5.
Paz-Ares L, Juan-Vidal O, Mountzios G, Felip E, Reinmuth N, de Marinis F, et al.
J Clin Oncol
. 2024 Jun;
42(24):2860-2872.
PMID: 38843511
Purpose: The open-label, phase III EVOKE-01 study evaluated sacituzumab govitecan (SG) versus standard-of-care docetaxel in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based chemotherapy, anti-PD-(L)1, and targeted treatment...
6.
Xie M, Vuko M, Rodriguez-Canales J, Zimmermann J, Schick M, OBrien C, et al.
Mol Cancer
. 2024 May;
23(1):115.
PMID: 38811992
Background: We explored potential predictive biomarkers of immunotherapy response in patients with extensive-stage small-cell lung cancer (ES-SCLC) treated with durvalumab (D) + tremelimumab (T) + etoposide-platinum (EP), D + EP,...
7.
Garassino M, Torri V
N Engl J Med
. 2024 May;
390(19):1816-1818.
PMID: 38749039
No abstract available.
8.
Sebri V, Marzorati C, Dorangricchia P, Monzani D, Grasso R, Prelaj A, et al.
Cancer Med
. 2024 May;
13(9):e7159.
PMID: 38741546
Introduction: To date, lung cancer is one of the most lethal diagnoses worldwide. A variety of lung cancer treatments and modalities are available, which are generally presented during the patient...
9.
Repetto M, Garassino M, Loong H, Lopez-Rios F, Mok T, Peters S, et al.
Cancer Treat Rev
. 2024 May;
127:102733.
PMID: 38733648
Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are recurrent oncogenic drivers found in a variety of solid tumours, including lung cancer. Several tropomyosin receptor kinase (TRK) inhibitors have been developed...
10.
Bria E, Morgillo F, Garassino M, Ciardiello F, Ardizzoni A, Stefani A, et al.
Oncologist
. 2024 Feb;
29(5):e690-e698.
PMID: 38377176
Background: MAURIS is an Italian multicenter, open-label, phase IIIb ongoing trial, aiming at evaluating the safety and effectiveness of atezolizumab + carboplatin/etoposide in patients with newly diagnosed, extensive-stage small-cell lung...